|
Primary outcome
|
Hamilton Rating Scale for Depression (HRSD)
|
24-Item instrument with overall score range of 0–76
|
Measured at screening phase as baseline, end of each acute treatment week, and end of every 4 weeks during the follow-up phase
|
|
Secondary outcomes
|
Montgomery-Asberg Depression Rating Scale (MADRS)
|
10-Item instrument with overall score range of 0–60
|
Measured at screening phase as baseline, end of each acute treatment week, and end of every 4 weeks during the follow-up phase
|
|
Beck Depression Inventory (BDI)
|
21-Item self-report test with overall score range of 0–63
|
Measured at screening phase as baseline, end of each acute treatment week, and end of every 4 weeks during the follow-up phase
|
|
Beck Scale for Suicide Ideation (BSS)
|
21-Item self-report test with overall score range of 0–38 with last 2 items not counted in scoring
|
Measured at screening phase as baseline, end of each acute treatment week, end of each taper week and week 4, and end of every 4 weeks during the follow-up phase
|
|
Veterans RAND 36-Item Health Survey (VR-36)
|
A self-administered survey consisting of two parts, i.e. Physical Component Summary (PCS, standardized score range of 0–100) and Mental Component Summary (MCS, standardized score range of 0–100)
|
Measured at screening phase as baseline, end of the acute treatment phase, and end of the follow-up phase
|
|
Neuropsychological Battery
|
A cognitive function test including measures of executive function, attention, memory, visuospatial ability, processing speed, psychomotor function, and premorbid intelligence
|
Measured at screening phase as baseline, end of the acute treatment phase, and end of the follow-up phase
|
